Spanish Red Cross Nursing School, Universidad de Sevilla, Avda de la Cruz Roja nº 1 Dpdo, 41009 Seville, Spain.
Hospital Virgen del Rocío, Unidad de Anestesiología y Reanimación, Servicio Andaluz de Salud, Av. Manuel Siurot, SN., 41013 Seville, Spain.
Nutrients. 2020 Aug 28;12(9):2628. doi: 10.3390/nu12092628.
(1) Background: Inflammatory bowel diseases are pathologies of unknown etiology and auto-immune pathogenia. The use of probiotics is studied in order to increase the arsenal of treatments. The aim was to assess the efficacy of the probiotics in these diseases in the active or quiescent phases; (2) Methods: A systematic review with meta-analysis was performed by an exhaustive bibliographic search in Medline, Cinahl, Embase, Scopus, Web of Science, and Cochrane Library. The inclusion criteria were studies of more than 10 years, English/Spanish, clinical trials, and involving human beings. Relative risk was used to compare efficacy, which was meta-analyzed using a fixed effects model. Heterogeneity was evaluated with the Higgins I test; (3) Results: Nineteen studies were included in the systematic review and 17 in the meta-analysis, with a total of 1537 patients ( = 762; = 775). There are significant remission differences in ulcerative colitis (relative risk (RR) = 0.81; 95% CI = 0.72-0.91; I = 32%; = 0.16). However, no significant differences were found in the use of probiotics for the prevention of ulcerative colitis, and for the remission of Crohn's disease; (4) Conclusions: There are data showing an additional beneficial effect of probiotics on active ulcerative colitis. More and better studies are needed which assess its possible therapeutic efficacy for quiescent ulcerative colitis and for Crohn's disease.
(1) 背景：炎症性肠病是病因不明和自身免疫发病机制的疾病。正在研究使用益生菌来增加治疗手段。目的是评估益生菌在这些疾病的活动期或缓解期的疗效；(2) 方法：通过对 Medline、Cinahl、Embase、Scopus、Web of Science 和 Cochrane Library 进行全面文献检索，进行了系统评价和荟萃分析。纳入标准为超过 10 年的研究、英文/西班牙文、临床试验和涉及人类的研究。相对风险用于比较疗效，采用固定效应模型进行荟萃分析。采用 Higgins I 检验评估异质性；(3) 结果：系统评价纳入了 19 项研究，荟萃分析纳入了 17 项研究，共纳入 1537 名患者（ = 762； = 775）。溃疡性结肠炎的缓解率存在显著差异（相对风险（RR）= 0.81；95%置信区间（CI）= 0.72-0.91；I = 32%； = 0.16）。然而，在使用益生菌预防溃疡性结肠炎和缓解克罗恩病方面，没有发现显著差异；(4) 结论：有数据表明益生菌对活动期溃疡性结肠炎有额外的有益作用。需要更多和更好的研究来评估其对缓解期溃疡性结肠炎和克罗恩病的可能治疗效果。
